Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer

Inclusion Criteria:

• Age: 18-80 years; Patients with histologically or cytologically confirmed,unresectable locally advanced or metastatic epithelial-derived malignant tumors whohave failed standard treatments, have no available standard treatment options, orare unsuitable for standard treatments at the current stage, including but notlimited to the following tumor types: non-small cell lung cancer or liver cancer;Immunohistochemistry (IHC) assessment shows GPC3 expression in ≥50% of the tumorlesion area with ≥1+ staining (assessment should be conducted on at least fiverandomly selected tumor regions, and at least five blank slides should be providedfor evaluation); At least one measurable lesion; Estimated survival time of ≥90days;

Normal major organ functions, meeting the following criteria: a. Absolute neutrophil count ≥1.5 x 10^9/L; b. Platelet count ≥80 x 10^9/L; c. Hemoglobin ≥9 g/dL; d. Liver function:

Total bilirubin ≤1.5 times the upper limit of normal (ULN), for Gilbert's syndrome patients, bilirubin ≤2.0 times ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times ULN; e. International Normalized Ratio (INR) <1.3 (for patients on anticoagulant therapy, INR <3 is acceptable); f. Serum creatinine ≤1.5 mg/dL (132.6 μmol/L) or estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m²; g. Left ventricular ejection fraction >50%; No hemorrhagic disorders or coagulation dysfunctions; Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days before enrollment and be willing to use appropriate contraception during the study and for 8 weeks after the last CAR-T administration (women who have undergone sterilization or are postmenopausal for at least 2 years are considered not to have childbearing potential); The subject voluntarily agrees to participate in the study, signs the informed consent form, and demonstrates good compliance for follow-up.

Exclusion Criteria:

• Pregnant or breastfeeding women; Receipt of chemotherapy, targeted therapy, otherexperimental drugs, or monoclonal antibody treatment within 14 days beforeenrollment for cell collection; Participation in other drug clinical trials within 4weeks prior to the start of the study; Presence of any of the followingcardiovascular or cerebrovascular diseases or risk factors: a. Myocardialinfarction, unstable angina, acute or persistent myocardial ischemia, grade 3 or 4heart failure (according to NYHA classification), symptomatic or poorly controlledsevere arrhythmia, cerebrovascular accident, transient ischemic attack, or otherserious cardiovascular diseases within 6 months prior to enrollment; b. History ofmyocarditis, primary cardiomyopathy, or specific cardiomyopathy; c. Any events ofdisseminated intravascular coagulation (DIC), peripheral arterial thromboembolism,pulmonary embolism, or other severe thromboembolic events within 3 months prior toenrollment; d. Presence of aortic aneurysm, aortic dissection, or other majorvascular diseases requiring surgery within 6 months prior to enrollment or posing alife-threatening risk; e. QTcF interval >480 ms; f. Left ventricular ejectionfraction (LVEF) <50% on ECHO; Long-term unhealed wounds or fractures; History ofsubstance abuse or psychiatric disorders that cannot be controlled or a history ofmental illness; Uncontrolled or active fungal, bacterial, viral, or otherinfections; Toxicities from previous anti-tumor treatments not yet recovered tograde ≤1 or to the levels specified in the inclusion/exclusion criteria; Known HIVinfection; active syphilis infection; or active hepatitis B (HBsAg positive, andHBV-DNA ≥500 IU/mL or above the detection limit, whichever is higher) or hepatitis C (HCV antibody positive, and HCV-RNA above the detection limit); Uncontrollablepleural effusion, pericardial effusion, or ascites requiring repeated drainagedespite appropriate intervention; History of severe allergic reactions to key studymedications (including fludarabine, cyclophosphamide, mesna, tocilizumab, oranti-infection drugs used during the preconditioning phase); Active autoimmunediseases requiring systemic treatment within two years (including but not limited toautoimmune hepatitis, uveitis, colitis, hypophysitis, vasculitis, nephritis, orhyperthyroidism); hormone replacement therapy, such as thyroid hormones, insulin, orphysiological corticosteroid replacement for adrenal or pituitary insufficiency, isnot considered systemic treatment; Female subjects unwilling to use contraceptionfrom the time of signing the consent form until 6 months after completion of CAR-Tcell infusion; Patients with meningeal metastasis, brainstem metastasis, spinal cordmetastasis and/or compression, active or untreated CNS metastasis; History ofinterstitial lung disease (ILD) or non-infectious pneumonia requiring steroidtreatment; Clinically significant lung damage due to pulmonary complications,including but not limited to any underlying lung disease (e.g., pulmonary embolism,severe asthma, or severe chronic obstructive pulmonary disease (COPD) within 3months prior to enrollment), or any autoimmune, connective tissue, or inflammatorydisease affecting the lungs (e.g., rheumatoid arthritis, sarcoidosis), or priorcomplete lung resection; Any condition that the investigator believes may interferewith drug evaluation, the safety of the subject, or study outcomes, or any conditiondeemed inappropriate by the investigator for study participation.